Iovance Biotherapeutics to Present Data at Upcoming ESMO 2017 Congress on Tumor-Infiltrating Lymphocyte Treatment for Lymphoma Indications Read more about Iovance Biotherapeutics to Present Data at Upcoming ESMO 2017 Congress on Tumor-Infiltrating Lymphocyte Treatment for Lymphoma Indications
Iovance Biotherapeutics Announces First Patient Dosed in C-145-04 Phase 2 Trial in Cervical Cancer Read more about Iovance Biotherapeutics Announces First Patient Dosed in C-145-04 Phase 2 Trial in Cervical Cancer
Iovance Biotherapeutics Appoints Timothy Morris as Chief Financial Officer Read more about Iovance Biotherapeutics Appoints Timothy Morris as Chief Financial Officer
Iovance Biotherapeutics to Host Conference Call to Discuss Second Quarter 2017 Financial and Operating Results on Tuesday, August 1, 2017 Read more about Iovance Biotherapeutics to Host Conference Call to Discuss Second Quarter 2017 Financial and Operating Results on Tuesday, August 1, 2017
Lion Biotechnologies, Inc. Changes Name to Iovance Biotherapeutics, Inc. Read more about Lion Biotechnologies, Inc. Changes Name to Iovance Biotherapeutics, Inc.
Lion Biotechnologies Announces Updated Data at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting from Ongoing LN-144 Phase 2 Clinical Trial Read more about Lion Biotechnologies Announces Updated Data at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting from Ongoing LN-144 Phase 2 Clinical Trial
Lion Biotechnologies Announces First Patient Dosed in Phase 2 Trial of LN-145 for Head and Neck Cancer Read more about Lion Biotechnologies Announces First Patient Dosed in Phase 2 Trial of LN-145 for Head and Neck Cancer
Lion Biotechnologies to Present at Jefferies 2017 Healthcare Conference Read more about Lion Biotechnologies to Present at Jefferies 2017 Healthcare Conference
Lion Biotechnologies to Raise Approximately $23 Million in Private Financing Read more about Lion Biotechnologies to Raise Approximately $23 Million in Private Financing
Lion Biotechnologies Completes $23.3 Million Private Financing Read more about Lion Biotechnologies Completes $23.3 Million Private Financing